Theralase shows how PDT can destroy cancer, bacteria, viruses, and fat cells

February 28, 2008, Toronto, Ont., Canada--Theralase Technologies, a developer, manufacturer and distributor of therapeutic medical laser systems, has achieved positive research and development results in the destruction of individual cancer cell lines. This research is aimed at combining patented photodynamic compounds (PDCs), under exclusive worldwide license to Theralase, with the company's patented bio-feedback laser technology for the selective destruction of cancers, bacteria, viruses, and fat cells.

Theralase, in conjunction with University Health Network, Virginia Tech and with financial support from the Ontario Centres of Excellence's Centre for Photonics, commenced a project in July 2007 focused on assessing the therapeutic potential of various PDCs in combination with the company's patented laser technology. The TLC-3000 project involves progressive assessment of the destruction of cancerous cells in: individual cancer cell lines, small animals, large animals and humans.

"Theralase is pleased to achieve the first milestone in our PDC project aimed at combining the power of PDCs with our laser technology in the destruction of cancerous cells," said Roger Dumoulin-White, President and CEO of Theralase. "We expect to release the final results in a publication or scientific symposium in the next few months."

Independent laboratory research has now confirmed significant efficacy of all three PDCs, under assessment, in successfully killing brain cancer and colon cancer cell lines. The PDCs employed in the trials have proven the ability to selectively target cancerous cells over cells derived from healthy tissue. Additional cancer cell lines and various bacterial species will be evaluated in the next stage of the project to determine cell kill by the PDCs.

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

(SLIDESHOW) View the July/August 2013 issue

ONCOLOGY/CANCER TREATMENT: Study reveals potential of terahertz pulses to fight cancer

Terahertz (THz) photons don't have sufficient energy to break apart the bonds that bind DNA in a cell's nucleus.

OPTOACOUSTICS/OXIMETRY: Real-time photoacoustics beats pulse oximetry by measuring oxygenation in single cells

Red blood cells ferry oxygen to a body's cells and tissues by way of arteries, veins, and capillaries.

SPECTROSCOPY/ONCOLOGY/GYNECOLOGY: First-ever minimally invasive ovarian cancer screen is spectroscopy-based

Researchers at Northwestern University and NorthShore University HealthSystem have previously demonstrated the ability of partial-wave spectroscopy to detect subtle changes in cells that indicate c...


Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS